Towards patient-specific tumor antigen selection for vaccination.
about
Fever therapy revisitedAdoptive T cell therapy for cancer in the clinicCancer immunotherapy: the beginning of the end of cancer?Cancer immunotherapy comes of ageProteomics in cancer vaccine development.The sentinel within: exploiting the immune system for cancer biomarkers.Principles of adoptive T cell cancer therapy.HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.Cancer prevention and therapy: strategies and problems.T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Recent developments in human papillomavirus vaccines.Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.DNA vaccines to attack cancerAdenovirus as vehicle for anticancer genetic immunotherapy.Contribution of mass spectrometry-based proteomics to immunology.Identification of T-cell epitopes for cancer immunotherapy.Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.HLA ligandome tumor antigen discovery for personalized vaccine approach.Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells.Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues.Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up.Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer.Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
P2860
Q24650460-13AA6B74-EC56-4960-8512-1F81F0273D3DQ24680405-D9106A76-E158-4B8B-81A8-A33D00D221C8Q26752277-B8E25098-7B83-4541-B6A8-44D80B11487FQ29619918-B406211F-3ED5-4017-9CF9-8EDFA18CFD0EQ33215044-75641DE9-D316-447A-A48F-3663B6D5399FQ33221191-0DF44DFB-8604-41E6-BAA9-8801DE2599F4Q34003932-B7440CB5-0CBF-4B65-B9C9-E265F383E3C1Q34985471-B2B6785C-43A1-4107-A35A-33A8DA167486Q35160569-B7A1C1E5-130D-484A-98A4-E723087AE77CQ35594641-66CB358A-FFD5-4F86-B67E-83D59F20F37CQ35728607-C666E003-B30F-4170-8A19-4B9F65CEABE9Q35826392-2A199EEB-CE69-4C2E-A0F2-389B5BDC09CCQ35842528-64A3D6A4-1D3E-4AB4-AF3A-13434E5A4749Q35850673-32FF88FA-7DF9-4C99-ABD5-6015FECD119EQ35855143-71324E0C-382D-4C92-9F9D-E4CCC18E2982Q36288930-D97EDCE4-F444-42B8-8494-CC95FDCE5622Q36689114-2BACF964-60B9-451C-8836-040D6E867A4EQ36870592-8ACCF1E5-BE18-4D97-B27E-677A300B037BQ37456000-3559C212-94CD-4966-85DD-FE9A3CEA3271Q38148779-D20CC217-87C8-45BC-AB2A-9A910EF639DBQ38952717-305BF391-B8A3-44EF-A8DE-A6ACEF4DD36EQ39698552-EB5364E2-7EEE-42FE-8E7A-AF00B93A08A5Q40057214-3E83E417-EF86-403F-BA77-69A85609E4BAQ41842804-717FB4DA-035B-4694-B073-FFD7E256C036Q43102307-5F1987EA-67BC-44EB-945A-9BFBD43F362AQ46090804-35BEC2D6-1245-4818-8268-5E5745F641FBQ51583278-D7B208D5-4C8A-4DC8-AE18-FFC073B2651EQ56986695-B7AF297F-7F44-4498-B5F7-596205F12394
P2860
Towards patient-specific tumor antigen selection for vaccination.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Towards patient-specific tumor antigen selection for vaccination.
@ast
Towards patient-specific tumor antigen selection for vaccination.
@en
type
label
Towards patient-specific tumor antigen selection for vaccination.
@ast
Towards patient-specific tumor antigen selection for vaccination.
@en
prefLabel
Towards patient-specific tumor antigen selection for vaccination.
@ast
Towards patient-specific tumor antigen selection for vaccination.
@en
P2860
P50
P1476
Towards patient-specific tumor antigen selection for vaccination.
@en
P2093
Toni Weinschenk
P2860
P304
P356
10.1034/J.1600-065X.2002.18815.X
P577
2002-10-01T00:00:00Z